(ENOV) Enovis - Ratings and Ratios
Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US1940145022
ENOV EPS (Earnings per Share)
ENOV Revenue
ENOV: Orthopedic Braces, Joint Implants, Surgical Tools, Compression Garments, Therapy
Enovis Corporation is a medical technology company that develops and markets clinically differentiated solutions globally, operating through two primary segments: Prevention and Recovery, and Reconstructive. The Prevention and Recovery segment offers a range of orthopedic solutions, including bracing, therapy products, and compression garments used by various healthcare professionals. The Reconstructive segment focuses on surgical implants for joint reconstruction and surgical productivity tools. Enovis distributes its products under the ESAB and DJO brands, both directly and through independent distributors.
From a business perspective, Enovis has a diversified product portfolio catering to different healthcare needs, from orthopedic care to reconstructive surgery. The companys products are used by a wide range of healthcare professionals, indicating a broad customer base. Its distribution strategy, combining direct sales with independent distributors, allows for a wide market reach.
Analyzing the provided
From a fundamental standpoint, as per the
Forecasting the stocks performance using both technical and fundamental data, the current downtrend and low RoE are concerning. However, the forward P/E ratio suggests potential for growth if the company can improve its earnings. A potential trading strategy could involve monitoring the stocks ability to break above its SMA20 and SMA50 levels, which could indicate a reversal in the short-term downtrend. Additionally, keeping an eye on the companys future earnings reports and guidance will be crucial, as an improvement in RoE and profitability could positively impact the stock price.
Given the current technical and fundamental landscape, a cautious approach is warranted. Investors should watch for signs of trend reversal and improvements in the companys financial health before making significant investment decisions.
Additional Sources for ENOV Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle
ENOV Stock Overview
Market Cap in USD | 1,916m |
Sector | Healthcare |
Industry | Medical Devices |
GiC Sub-Industry | Health Care Equipment |
IPO / Inception | 2008-05-08 |
ENOV Stock Ratings
Growth Rating | -52.3 |
Fundamental | -54.5 |
Dividend Rating | 0.0 |
Rel. Strength | -26.3 |
Analysts | 4.55 of 5 |
Fair Price Momentum | 25.68 USD |
Fair Price DCF | - |
ENOV Dividends
Currently no dividends paidENOV Growth Ratios
Growth Correlation 3m | -53.6% |
Growth Correlation 12m | -62.6% |
Growth Correlation 5y | -69.1% |
CAGR 5y | -8.25% |
CAGR/Max DD 5y | -0.12 |
Sharpe Ratio 12m | -1.61 |
Alpha | -41.61 |
Beta | 0.941 |
Volatility | 46.38% |
Current Volume | 1307.2k |
Average Volume 20d | 1166k |
As of June 19, 2025, the stock is trading at USD 30.88 with a total of 1,307,153 shares traded.
Over the past week, the price has changed by -7.96%, over one month by -12.97%, over three months by -21.20% and over the past year by -31.38%.
No, based on ValueRay´s Fundamental Analyses, Enovis (NYSE:ENOV) is currently (June 2025) a stock to sell. It has a ValueRay Fundamental Rating of -54.52 and therefor a negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ENOV is around 25.68 USD . This means that ENOV is currently overvalued and has a potential downside of -16.84%.
Enovis has received a consensus analysts rating of 4.55. Therefor, it is recommend to buy ENOV.
- Strong Buy: 7
- Buy: 3
- Hold: 1
- Sell: 0
- Strong Sell: 0
According to our own proprietary Forecast Model, ENOV Enovis will be worth about 28.3 in June 2026. The stock is currently trading at 30.88. This means that the stock has a potential downside of -8.48%.
Issuer | Target | Up/Down from current |
---|---|---|
Wallstreet Target Price | 56.5 | 83% |
Analysts Target Price | 56.5 | 83% |
ValueRay Target Price | 28.3 | -8.5% |